Related Experiment Video

Updated: Mar 17, 2026

Measurement of Insulin- and Contraction-Stimulated Glucose Uptake in Isolated and Incubated Mature Skeletal Muscle from Mice
08:01

Measurement of Insulin- and Contraction-Stimulated Glucose Uptake in Isolated and Incubated Mature Skeletal Muscle from Mice

Published on: May 16, 2021

6.8K

AMPK Activators as a Drug for Diabetes, Cancer and Cardiovascular Disease

Mark Goodman1, Zhenling Liu2, Ping Zhu3

  • 1Department of Pharmacology and Toxicology, School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, NY 14214, USA.

Pharmaceutical Regulatory Affairs : Open Access
|August 2, 2016
PubMed

Insights

AMP-Activated Protein Kinase (AMPK) activators show promise for treating and preventing diabetes, cancer, and cardiovascular disease by targeting key cellular mechanisms. Further research into these pathways could lead to novel therapeutic strategies.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • AMP-Activated Protein Kinase (AMPK) is a crucial cellular energy sensor.
  • Dysregulation of AMPK signaling is implicated in metabolic and proliferative diseases.
  • AMPK activators are being investigated for therapeutic potential.

Purpose of the Study:

  • To elucidate the cellular mechanisms underlying the effects of AMPK activators.
  • To explore the role of AMPK activation in diabetes, cancer, and cardiovascular disease.
  • To identify potential therapeutic targets for these conditions.

Main Methods:

  • Review of existing literature on AMPK signaling pathways.
  • Analysis of cellular and molecular studies investigating AMPK activators.
  • Examination of preclinical and clinical data on AMPK-targeted therapies.

Main Results:

  • AMPK activation influences glucose uptake, lipid metabolism, and mitochondrial function.
  • AMPK plays a role in cell growth, proliferation, and apoptosis relevant to cancer.
  • AMPK signaling impacts endothelial function and cardiac energetics in cardiovascular disease.

Conclusions:

  • AMPK activators represent a promising therapeutic strategy for multiple chronic diseases.
  • Understanding AMPK's cellular mechanisms is key to developing effective treatments.
  • Targeting AMPK offers a unified approach for managing diabetes, cancer, and cardiovascular conditions.

More Related Videos

Live-Cell Förster Resonance Energy Transfer Imaging of Metabolically Regulated Akt Activation Dynamics in HepG2 Cells08:03

Live-Cell Förster Resonance Energy Transfer Imaging of Metabolically Regulated Akt Activation Dynamics in HepG2 Cells

Published on: May 23, 2025

861
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.8K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.1K
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
8.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.6K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K